September 26, 2018 | Brandon Underwood Frequently Asked Questions – 340B Program The 340B program is subject to increasing scrutiny as pharmaceutical manufacturers search for solutions to identify and act on non-compliance such as diversion and duplicate discounts. This post is taken from the Q&A session of IntegriChain's recent 340B webinar. Topics discussed include growth in contract pharmacies/covered entities, 340B discount pricing for orphan drugs, and validation of 340B entities. Read More Tags: 340B, 867, contract pharmacy, covered entity, Diversion, Duplicate Discounts, Enriched 867 Data, National data, Orphan Drugs, Subnational data
August 20, 2018 | Shivani Patel Opioid Crisis Exposes Vulnerabilities in Suspicious Order Monitoring The American opioid crisis exposed gaps in the reporting systems designed to flag suspicious orders of pharmaceutical products classified as controlled substances. Pharmaceutical manufacturers are now facing increased scrutiny and need new approaches to monitor and report on irregular order patterns for controlled substances. This post discusses a new approach that provides visibility across pharmacy locations and wholesale distributors while weaving in additional demographic insights. Read More Tags: chargebacks, Controlled Substances, Enriched 867 Data, Opioid Crisis, SOMS, Suspicious Order Monitoring
